Britain and America have signed a key commercial pact that will keep no import taxes on British pharmaceutical exports going into the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to increase funding on medicines through the public health system. This commitment ensures that import taxes on these crucial products will be held at zero for a duration of three years.
This development follows previous warnings to significantly raise tariffs on branded drug imports, with figures discussed reaching double the cost.
"This agreement with the Britain bolsters the worldwide climate for innovative medicines and establishes much-needed balance to U.S.–U.K. medicine commerce," an announcement declared.
Economic Importance
Drugs represent one of the UK's largest exports to the United States, which is easily the biggest buyer for large British pharmaceutical firms.
Export figures indicate that in the year to the end of last September, the UK sold pharmaceutical products worth over eleven billion pounds to the US. This value made up nearly one-fifth of British export trade in that span.
"This deal secures jobs, stimulates capital expenditure and sets the stage for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary remarked.
Detailed British Pledges
The pact entails several key changes from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new therapies to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to raise overall public funding on medicines from 0.3 percent of GDP to 0.6% over the next decade.
- Refund Ceiling: The sum drug companies must pay back to the NHS to prevent overspending will be limited at 15%. In the past, refunds were more than 20%.
Industry Background
This agreement comes amid a long-running dispute between the sector and the British authorities over drug pricing and NHS adoption.
This friction were intensified by arguments that American customers were charged several times more for the equivalent treatments than patients in the UK and Europe.
Recently, several large manufacturing plans in the UK have been halted or cancelled, while major investments have been announced toward American operations.
A senior figure publicly accepted that the NHS must increase expenditure on drugs, noting that its budget allocation on drugs had decreased as a percentage of its resources over the last ten years.
